aTyr Pharma Announces Fourth Quarter and Full Year 2020 Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq set to open higher as CPI, bank earnings take focus; IBM tumbles
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
aTyr Pharma (LIFE) Tops Q4 EPS by 35c
March 23, 2021 4:15 PM EDTaTyr Pharma (NASDAQ: LIFE) reported Q4 EPS of ($0.47), $0.35 better than the analyst estimate of ($0.82).
Amidst the backdrop of the COVID-19 pandemic, 2020 was a highly productive year for aTyr that included significant clinical, research and discovery advancements that we expect to yield value for the company throughout 2021, said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. We are highly encouraged by our... More
